HCC Resources

Here you will find relevant materials related to Nexavar® (sorafenib) and Stivarga® (regorafenib) in HCC, as well as links to relevant articles and publications.
National Institute for Health and Care Excellence (NICE) guidance. Sorafenib for treating advanced hepatocellular carcinoma.
National Institute for Health and Care Excellence (NICE) guidance. Regorafenib for previously treated advanced hepatocellular carcinoma.
Scottish Medicines Consortium. Detailed advice on regorafenib 40mg film-coated tablets (Stivarga). SMC No 1316/18.
European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of hepatocellular carcinoma.
PP-NEX-GB-0215 | February 2024